Astria Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2019 12 months to Dec 31, 2019
Operating expenses:
Research and development
General and administrative
Acquired in-process research and development
Total operating expenses
Loss from operations
Other income (expense):
Interest and investment income
Other expense, net
Total other income, net
Net loss
Net loss per share - basic and diluted (in dollars per share)
Weighted-average common shares outstanding used in net loss per share - basic and diluted (in shares)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs
Net loss attributable to common shareholders
Net loss per share attributable to common shareholders - basic
Net loss per share attributable to common shareholders - diluted
Weighted-average common shares outstanding used in net loss per share - basic
Weighted-average common shares outstanding used in net loss per share - diluted

Comments